Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
RemeGen Co. Ltd. Class H ( (HK:9995) ) has issued an update.
RemeGen Co., Ltd. has expanded its use of idle self-owned funds for cash management by purchasing a series of wealth management products from HTSC, totaling several hundred million renminbi. The purchases, approved by the board under a cash management mandate of up to RMB2.5 billion, reflect the company’s strategy to enhance returns on surplus cash while maintaining liquidity for its core biopharmaceutical operations.
Because all eight HTSC wealth management product agreements were entered into with the same financial institution within a 12‑month period and are similar in nature, the Hong Kong Listing Rules require their aggregation for disclosure purposes. The combined size of these transactions crosses the 5% threshold but remains below 25%, classifying them as a discloseable transaction and underscoring RemeGen’s growing use of financial instruments, with implications for investors monitoring its risk management and capital deployment policies.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$129.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a biopharmaceutical company headquartered in China and listed in Hong Kong under stock code 9995. The company focuses on developing and commercializing innovative therapies, and actively manages its capital structure and liquidity through the use of structured financial products and other treasury tools.
Average Trading Volume: 4,229,589
Technical Sentiment Signal: Buy
Current Market Cap: HK$63.37B
For a thorough assessment of 9995 stock, go to TipRanks’ Stock Analysis page.